NCT02487550View on ClinicalTrials.gov

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2030

Conditions
Renal Neoplasma
Interventions
BIOLOGICAL

DC-CIK

Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.

BIOLOGICAL

IL-2/IFN-α

Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER

NCT02487550 - DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating | Biotech Hunter | Biotech Hunter